HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial

Abstract This prospective study evaluated whether baseline cholesterol efflux is associated with future development of type 2 diabetes (T2DM) in cardiovascular patients. We measured cholesterol efflux in all CORDIOPREV study (NCT00924937) participants free of T2DM at baseline (n = 462) and assessed...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruth Blanco-Rojo, Pablo Perez-Martinez, Javier Lopez-Moreno, Javier Martinez-Botas, Javier Delgado-Lista, Ben van-Ommen, Elena Yubero-Serrano, Antonio Camargo, Jose M. Ordovas, Francisco Perez-Jimenez, Diego Gomez-Coronado, Jose Lopez-Miranda
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/62c638c704f146448cf3d2d3e785f790
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:62c638c704f146448cf3d2d3e785f790
record_format	dspace
spelling	oai:doaj.org-article:62c638c704f146448cf3d2d3e785f7902021-12-02T15:05:39ZHDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial10.1038/s41598-017-12678-92045-2322https://doaj.org/article/62c638c704f146448cf3d2d3e785f7902017-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-12678-9https://doaj.org/toc/2045-2322Abstract This prospective study evaluated whether baseline cholesterol efflux is associated with future development of type 2 diabetes (T2DM) in cardiovascular patients. We measured cholesterol efflux in all CORDIOPREV study (NCT00924937) participants free of T2DM at baseline (n = 462) and assessed its relationship with T2DM incidence during a 4.5 years of follow-up. Cholesterol efflux was quantified by incubation of cholesterol-loaded THP-1 cells with the participants’ apoB-depleted plasma. Disposition index was estimated as beta-cell function indicator. During follow-up 106 individuals progressed to T2DM. The cholesterol efflux/apoA-1 ratio was inversely associated with T2DM development independently of traditional risk factors (model-1, OR: 0.647, 95%CI: 0.495–0.846), and after additional adjustment for glycaemic parameters (model-2, OR: 0.670, 95%CI: 0.511–0.878). When cumulative incidence of diabetes was analysed by quartiles of cholesterol efflux/apoA-I, incidence of T2DM was reduced by 54% in subjects who were in the higher cholesterol efflux/apoA-I quartile compared to subjects in the lowest quartile (p = 0.018 and p = 0.042 for model-1 and 2). Moreover, participants who were in the higher cholesterol efflux/apoA-I presented significantly higher disposition index (β = 0.056, SE = 0.026; p = 0.035). In conclusion, HDL-cholesterol efflux normalised to apoA-I was inversely associated with T2DM development in cardiovascular patients. This association was independent of several T2DM risk factors, and may be related to a preserved beta-cell function.Ruth Blanco-RojoPablo Perez-MartinezJavier Lopez-MorenoJavier Martinez-BotasJavier Delgado-ListaBen van-OmmenElena Yubero-SerranoAntonio CamargoJose M. OrdovasFrancisco Perez-JimenezDiego Gomez-CoronadoJose Lopez-MirandaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ruth Blanco-Rojo Pablo Perez-Martinez Javier Lopez-Moreno Javier Martinez-Botas Javier Delgado-Lista Ben van-Ommen Elena Yubero-Serrano Antonio Camargo Jose M. Ordovas Francisco Perez-Jimenez Diego Gomez-Coronado Jose Lopez-Miranda HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial
description	Abstract This prospective study evaluated whether baseline cholesterol efflux is associated with future development of type 2 diabetes (T2DM) in cardiovascular patients. We measured cholesterol efflux in all CORDIOPREV study (NCT00924937) participants free of T2DM at baseline (n = 462) and assessed its relationship with T2DM incidence during a 4.5 years of follow-up. Cholesterol efflux was quantified by incubation of cholesterol-loaded THP-1 cells with the participants’ apoB-depleted plasma. Disposition index was estimated as beta-cell function indicator. During follow-up 106 individuals progressed to T2DM. The cholesterol efflux/apoA-1 ratio was inversely associated with T2DM development independently of traditional risk factors (model-1, OR: 0.647, 95%CI: 0.495–0.846), and after additional adjustment for glycaemic parameters (model-2, OR: 0.670, 95%CI: 0.511–0.878). When cumulative incidence of diabetes was analysed by quartiles of cholesterol efflux/apoA-I, incidence of T2DM was reduced by 54% in subjects who were in the higher cholesterol efflux/apoA-I quartile compared to subjects in the lowest quartile (p = 0.018 and p = 0.042 for model-1 and 2). Moreover, participants who were in the higher cholesterol efflux/apoA-I presented significantly higher disposition index (β = 0.056, SE = 0.026; p = 0.035). In conclusion, HDL-cholesterol efflux normalised to apoA-I was inversely associated with T2DM development in cardiovascular patients. This association was independent of several T2DM risk factors, and may be related to a preserved beta-cell function.
format	article
author	Ruth Blanco-Rojo Pablo Perez-Martinez Javier Lopez-Moreno Javier Martinez-Botas Javier Delgado-Lista Ben van-Ommen Elena Yubero-Serrano Antonio Camargo Jose M. Ordovas Francisco Perez-Jimenez Diego Gomez-Coronado Jose Lopez-Miranda
author_facet	Ruth Blanco-Rojo Pablo Perez-Martinez Javier Lopez-Moreno Javier Martinez-Botas Javier Delgado-Lista Ben van-Ommen Elena Yubero-Serrano Antonio Camargo Jose M. Ordovas Francisco Perez-Jimenez Diego Gomez-Coronado Jose Lopez-Miranda
author_sort	Ruth Blanco-Rojo
title	HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial
title_short	HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial
title_full	HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial
title_fullStr	HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial
title_full_unstemmed	HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial
title_sort	hdl cholesterol efflux normalised to apoa-i is associated with future development of type 2 diabetes: from the cordioprev trial
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/62c638c704f146448cf3d2d3e785f790
work_keys_str_mv	AT ruthblancorojo hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT pabloperezmartinez hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT javierlopezmoreno hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT javiermartinezbotas hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT javierdelgadolista hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT benvanommen hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT elenayuberoserrano hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT antoniocamargo hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT josemordovas hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT franciscoperezjimenez hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT diegogomezcoronado hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial AT joselopezmiranda hdlcholesteroleffluxnormalisedtoapoaiisassociatedwithfuturedevelopmentoftype2diabetesfromthecordioprevtrial
_version_	1718388767427919872

HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial

Ejemplares similares